Angioedema and angiotensin-II receptor blockers
admin October 6th, 2009
Angioedema is a rare serious adverse drug reaction (ADR) to angiotensin-converting enzyme inhibitors (ACE-I), with an incidence of 0.1% to 1.0%. If untreated it can be life-threatening. Debate exists over the safety of switching to an angiotensin-II receptor blocker (ARB), due to case reports of angioedema, and the mechanism of ARB-associated angioedema. The DoTS system of ADR classification provides a structured template for examining the Dose and Time relationship, and potential Susceptabilities to an ADR.
Here is a poster we are presenting at the International Society of Pharmacovigilance conference this week.
Angioedema associated with angiotensin-II receptor blockers: a DoTS classification
and analysis [PDF].
- ADRs , Our research
- Comments Off